ODAC Looks Beyond Dacogen Study’s Statistical Failure, But Still Finds Little Support For New Use
Executive Summary
In evaluating a new leukemia indication for Eisai’s Dacogen, the Oncologic Drugs Advisory Committee and FDA reviewers showed they are willing to look beyond a missed efficacy endpoint, but only if the supportive evidence of benefit is really solid. Ten of 14 committee members ultimately concluded that decitabine did not have a favorable risk-benefit profile for elderly AML patients.
You may also be interested in...
Eisai Will Make “Totality Of The Evidence” Argument At FDA Panel Review Of Dacogen
Briefing documents for the Oncologic Drugs Advisory Committee’s Feb. 9 meeting suggest Eisai will argue that the totality of the data on decitabine’s efficacy and safety in elderly patients with acute myelogenous leukemia is sufficient to overcome the pivotal trial’s failure to show a statistically significant overall survival benefit in the primary analysis. In contrast, FDA’s review takes a laser-like focus on the failed primary endpoint.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.